We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Molecular Automation Is Changing Clinical Laboratories

By LabMedica International staff writers
Posted on 02 Jan 2018
Most mid-career laboratory medicine professionals find it hard not to recall the days when DNA had to be extracted manually and polyacrylamide gels were mixed by hand without also reflecting on how fast things have changed.

Automation has come so far, in fact, that it is poised to disrupt the very structure of molecular diagnostics laboratories. More...
New molecular automation systems are capable of connecting directly to clinical chemistry and immunoassay lines, potentially moving high-volume testing out of molecular diagnostics entirely.

Frederick S. Nolte, PhD, D(ABMM), F(AAM), the director of the clinical laboratories at the Medical University of South Carolina (Charleston, SC, USA) has explored the current situation as regards automation of molecular testing in the clinical laboratory. His laboratory uses the Abbott m2000 system (Abbott Molecular, Des Plaines, IL, USA) for molecular testing and also Abbott’s automation line. He wondered if he could take a single sample from hepatitis C virus (HCV) serological testing and also use it to perform molecular confirmatory testing. He conducted a study alternating HCV-positive samples with negative samples and found a very low level of cross-contamination in about 5% of samples. His laboratory went ahead with the new single-sample routine, but if the RNA result is below a certain threshold the staff asks for a new specimen.

The Cobas 6800 (Roche Molecular Diagnostics, Branchburg Township, NJ, USA) with the right connection modules, already uses a single sample for serology and molecular testing. It also uses information technology to control the testing workflow and incorporates intelligent rules for reflex testing. Molecular testing will inevitably integrate with chemistry testing in the coming years and that automation will continue to improve the ability of the laboratory to do more with fewer people.

The TriCore Reference Laboratories (Albuquerque, NM, USA) performs about 75,000 to 80,000 tests per month, on their recently installed the Roche Cobas 6800. Karissa Culbreath, PhD, D(ABMM), the scientific director of infectious diseases, said, “We can do more because now I’m able to free up my extremely talented molecular scientists and molecular technologists to work on the next wave of clinical infectious disease tests. Automation is not new; it's just new to clinical microbiology.” The study was published on December 1, 2017, in Clinical Laboratory News.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.